Evogene to Establish Evofuel Ltd. for Developing Advanced Feedstock for Biofuel
Wholly owned Subsidiary Expanding Castor Bean Activity in Brazil
Evogene Ltd. announced that it is establishing Evofuel, a wholly owned subsidiary, to focus on developing seed for advanced second-generation feedstock for biofuel. Included in the activities that are being transferred from the parent company to Evofuel is the development and commercialization of castor bean varieties for Brazil as well as the biofuel research and development activities located in Israel.
Evogene's biofuel activity, initiated in 2007, targets the development of second generation feedstock to serve as a sustainable, viable and cost efficient source of oil for the growing biodiesel industry. In addition to its activity for development and of advanced castor bean seed, Evofuel intends to broaden its activity to additional potential feedstocks for the biodiesel, biojet and bioethanol markets.
"With the biofuel industry’s continued growth and tremendous demand for cost competitive feedstock, there is a strong and immediate need for a solution based on designated second generation seed products. The establishment of Evofuel as a separate company, strongly positions it to address this substantial un-met need." stated Ofer Haviv, Evogene's President and CEO, "We are reinforced by the progress and results of our castor seed in Brazil and believe that access to Evogene’s leading plant genomics capabilities will provide Evofuel with commercial advantages and opportunities in relevant markets."
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Category:Genes_on_chromosome_4
Vitamin_K_epoxide_reductase

Lung Tissue from the Lab - Organoids could be used in diagnosis, drug development, and fundamental research

Coronavirus data analysis - Open source platform enables the free and transparent overview of COVID-19 genome informations
BioEquality: Improving the Safety of Gene Technologically Manufactured Biopharmaceuticals
Vibrations key to efficiency of green fluorescent protein - Charting femtosecond energy flow could aid redesign of molecules to improve light capture
Seiji_Ogawa

Celsius® FS16 | Filling stations | Sartorius
Corcept Therapeutics and Xceleron sign agreement for microdosing study using accelerator mass spectrometry
